trending Market Intelligence /marketintelligence/en/news-insights/trending/a4ltZU5nTUGWKSyyIR0BgQ2 content esgSubNav
In This List

Integrated Biopharma fiscal Q1 profit falls YOY

Case Study

A Green Lender Adopts a Robust Approach for Assessing Project Finance Credit Risks

Case Study

An Asset Manager Meets Client Redistribution Demands for Excel-based Statements

Podcast

MediaTalk | Season 2
Ep.1: Broadcast's Big Year

Blog

Global M&A by the Numbers Q4 2023


Integrated Biopharma fiscal Q1 profit falls YOY

Integrated Biopharma said its normalized net income for the fiscal first quarter ended Sept. 30 was $168,130, a decrease of 37.7% from $270,000 in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin declined to 1.8% from 3.1% in the year-earlier period.

Total revenue rose 10.1% year over year to $9.4 million from $8.6 million, and total operating expenses increased 10.2% from the prior-year period to $9.0 million from $8.1 million.

Reported net income decreased 29.2% year over year to $211,550, or 1 cent per share, from $299,000, or 1 cents per share.